201 related articles for article (PubMed ID: 24094075)
1. Rho-kinase inhibitors offer a new approach in the treatment of glaucoma.
Challa P; Arnold JJ
Expert Opin Investig Drugs; 2014 Jan; 23(1):81-95. PubMed ID: 24094075
[TBL] [Abstract][Full Text] [Related]
2. Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma.
Sturdivant JM; Royalty SM; Lin CW; Moore LA; Yingling JD; Laethem CL; Sherman B; Heintzelman GR; Kopczynski CC; deLong MA
Bioorg Med Chem Lett; 2016 May; 26(10):2475-2480. PubMed ID: 27072905
[TBL] [Abstract][Full Text] [Related]
3. Rho-kinase inhibitors in the management of glaucoma.
Berrino E; Supuran CT
Expert Opin Ther Pat; 2019 Oct; 29(10):817-827. PubMed ID: 31573364
[No Abstract] [Full Text] [Related]
4. Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research.
Rao PV; Pattabiraman PP; Kopczynski C
Exp Eye Res; 2017 May; 158():23-32. PubMed ID: 27593914
[TBL] [Abstract][Full Text] [Related]
5. Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility.
Abbhi V; Piplani P
Curr Med Chem; 2020; 27(14):2222-2256. PubMed ID: 30378487
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers and special features of oxidative stress in the anterior segment of the eye linked to lens cataract and the trabecular meshwork injury in primary open-angle glaucoma: challenges of dual combination therapy with N-acetylcarnosine lubricant eye drops and oral formulation of nonhydrolyzed carnosine.
Babizhayev MA
Fundam Clin Pharmacol; 2012 Feb; 26(1):86-117. PubMed ID: 21883446
[TBL] [Abstract][Full Text] [Related]
7. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.
Honjo M; Tanihara H
Jpn J Ophthalmol; 2018 Mar; 62(2):109-126. PubMed ID: 29445943
[TBL] [Abstract][Full Text] [Related]
8. The Application of Rho Kinase Inhibitors in the Management of Glaucoma.
Liu LC; Chen YH; Lu DW
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891764
[TBL] [Abstract][Full Text] [Related]
9. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.
Inoue T; Tanihara H
Expert Opin Pharmacother; 2017 Oct; 18(15):1669-1673. PubMed ID: 28893104
[TBL] [Abstract][Full Text] [Related]
10. Rho Kinase Inhibitors and Novel Ocular Drug Delivery Systems- A Revolutionary Step Towards the Treatment of Glaucoma.
Abbhi V; Piplani P
Curr Drug Deliv; 2016; 13(6):818-29. PubMed ID: 23855668
[TBL] [Abstract][Full Text] [Related]
11. Rho-associated kinase inhibitors: a novel glaucoma therapy.
Inoue T; Tanihara H
Prog Retin Eye Res; 2013 Nov; 37():1-12. PubMed ID: 23770081
[TBL] [Abstract][Full Text] [Related]
12. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma.
Komizo T; Ono T; Yagi A; Miyata K; Aihara M
Jpn J Ophthalmol; 2019 Jan; 63(1):40-45. PubMed ID: 30368633
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel inhibitors for the treatment of glaucoma.
Cholkar K; Trinh HM; Pal D; Mitra AK
Expert Opin Drug Discov; 2015 Mar; 10(3):293-313. PubMed ID: 25575654
[TBL] [Abstract][Full Text] [Related]
14. Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension.
Kopczynski CC; Heah T
Drugs Today (Barc); 2018 Aug; 54(8):467-478. PubMed ID: 30209441
[TBL] [Abstract][Full Text] [Related]
15. The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma.
Pakravan M; Beni AN; Ghahari E; Varshochian R; Yazdani S; Esfandiari H; Ahmadieh H
Am J Ther; 2017; 24(6):e676-e680. PubMed ID: 26825486
[TBL] [Abstract][Full Text] [Related]
16. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
Acta Ophthalmol; 2015 Jun; 93(4):e254-60. PubMed ID: 25487877
[TBL] [Abstract][Full Text] [Related]
17. AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia.
Van de Velde S; Van Bergen T; Sijnave D; Hollanders K; Castermans K; Defert O; Leysen D; Vandewalle E; Moons L; Stalmans I
Invest Ophthalmol Vis Sci; 2014 Feb; 55(2):1006-16. PubMed ID: 24474276
[TBL] [Abstract][Full Text] [Related]
18. Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy.
Sato S; Hirooka K; Nitta E; Ukegawa K; Tsujikawa A
Adv Ther; 2016 Sep; 33(9):1628-34. PubMed ID: 27438467
[TBL] [Abstract][Full Text] [Related]
19. Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics.
Van de Velde S; De Groef L; Stalmans I; Moons L; Van Hove I
Prog Neurobiol; 2015 Aug; 131():105-19. PubMed ID: 26093354
[TBL] [Abstract][Full Text] [Related]
20. Rho kinase inhibitors: a patent review (2014 - 2016).
Defert O; Boland S
Expert Opin Ther Pat; 2017 Apr; 27(4):507-515. PubMed ID: 28048944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
